S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
How to use A.I. to trade during an election year? (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
How to profit from the new boom in gold (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
How to profit from the new boom in gold (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
How to use A.I. to trade during an election year? (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
How to profit from the new boom in gold (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
How to profit from the new boom in gold (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
How to use A.I. to trade during an election year? (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
How to profit from the new boom in gold (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
How to profit from the new boom in gold (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
How to use A.I. to trade during an election year? (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
How to profit from the new boom in gold (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
How to profit from the new boom in gold (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:IKNA

Ikena Oncology (IKNA) Stock Price, News & Analysis

$1.43
-0.08 (-5.30%)
(As of 02/29/2024 ET)
Today's Range
$1.36
$1.54
50-Day Range
$1.27
$2.26
52-Week Range
$1.02
$7.64
Volume
773,522 shs
Average Volume
425,467 shs
Market Capitalization
$69.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Ikena Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
645.9% Upside
$10.67 Price Target
Short Interest
Healthy
2.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Ikena Oncology in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.63) to ($1.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.79 out of 5 stars

Medical Sector

465th out of 958 stocks

Biological Products, Except Diagnostic Industry

73rd out of 153 stocks

IKNA stock logo

About Ikena Oncology Stock (NASDAQ:IKNA)

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

IKNA Stock Price History

IKNA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Ikena Oncology Inc (IKNA)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Ikena Oncology Inc IKNA
See More Headlines
Receive IKNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/01/2024
Next Earnings (Estimated)
3/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IKNA
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.67
High Stock Price Target
$13.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+645.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-68,760,000.00
Net Margins
-327.46%
Pretax Margin
-491.69%

Debt

Sales & Book Value

Annual Sales
$13.95 million
Book Value
$4.05 per share

Miscellaneous

Free Float
45,387,000
Market Cap
$69.01 million
Optionable
Not Optionable
Beta
0.27
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Mark Manfredi Ph.D. (Age 53)
    President, CEO & Director
    Comp: $803.9k
  • Dr. Jotin Marango M.D. (Age 45)
    Ph.D., CFO & Head of Corporate Development
    Comp: $581.42k
  • Mr. Bob Lally
    Senior Vice President of Finance & Operations
  • Dr. Michelle Zhang Ph.D.
    Chief Scientific Officer
  • Ms. Samantha Vuksanic
    Head of Human Resources
  • Mr. Jeffrey Ecsedy Ph.D. (Age 54)
    Chief Development Officer
  • Mr. Navin Parwani M.S.
    VP & Head of Quality
  • Ms. Sabine Ruppel Ph.D.
    VP & Head of Discovery
  • Mr. David Damphousse M.S.
    Senior Vice President of Clinical Development Operations
  • Dr. Caroline Germa M.D. (Age 51)
    Chief Medical Officer














IKNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ikena Oncology stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IKNA shares.
View IKNA analyst ratings
or view top-rated stocks.

What is Ikena Oncology's stock price target for 2024?

4 brokerages have issued 12-month price targets for Ikena Oncology's shares. Their IKNA share price targets range from $8.00 to $13.00. On average, they predict the company's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 645.9% from the stock's current price.
View analysts price targets for IKNA
or view top-rated stocks among Wall Street analysts.

How have IKNA shares performed in 2024?

Ikena Oncology's stock was trading at $1.97 at the start of the year. Since then, IKNA shares have decreased by 27.4% and is now trading at $1.43.
View the best growth stocks for 2024 here
.

Are investors shorting Ikena Oncology?

Ikena Oncology saw a increase in short interest in February. As of February 15th, there was short interest totaling 662,400 shares, an increase of 18.4% from the January 31st total of 559,400 shares. Based on an average daily volume of 309,900 shares, the short-interest ratio is presently 2.1 days. Approximately 2.6% of the company's stock are short sold.
View Ikena Oncology's Short Interest
.

When is Ikena Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our IKNA earnings forecast
.

How were Ikena Oncology's earnings last quarter?

Ikena Oncology, Inc. (NASDAQ:IKNA) released its earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.02. The company earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million. Ikena Oncology had a negative trailing twelve-month return on equity of 42.27% and a negative net margin of 327.46%.

When did Ikena Oncology IPO?

(IKNA) raised $125 million in an initial public offering on Friday, March 26th 2021. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair acted as the underwriters for the IPO.

Who are Ikena Oncology's major shareholders?

Ikena Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (9.88%), Blue Owl Capital Holdings LP (4.05%), Vanguard Group Inc. (3.16%), Verition Fund Management LLC (2.74%), Vestal Point Capital LP (0.67%) and Barclays PLC (0.51%). Insiders that own company stock include Jean Francois Formela, Venture Fund Xi LP Atlas and Xiaoyan Michelle Zhang.
View institutional ownership trends
.

How do I buy shares of Ikena Oncology?

Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IKNA) was last updated on 3/1/2024 by MarketBeat.com Staff

From Our Partners